NOVADIP Biosciences S.A.

🚀 We are thrilled to participate in #LSIUSA25, the go-to #medtech event organized by LSI USA, presenting our latest clinical and business updates, March 17-21, in Dana Point, California.    🕥 On March 20, at 10:30am PST, Denis Dufrane will be presenting Novadip's cutting-edge technology platform, revolutionizing the standard of care for bone regeneration with the 1st true osteobiologic product.    💬 Interested in meeting up? Drop us a message and let's connect during the event.   Meanwhile, watch Denis’ video presentation from LSI USA ’24 #RegenerativeMedicine #BoneHealing #Orthopedics https://lnkd.in/deVEAD9p

Novadip is proud to support the UN International Day of Women and Girls in Science👩🔬   2025 marks the 10th anniversary of this important observance, and it’s more crucial than ever to encourage girls and women to pursue careers in STEM. Gender equality in science is essential to building a better future for all.    Today, we’re honoring 4 inspiring women who have been instrumental in the development of our technology platform:   🌟 Carmen Brenner, Quality Control Director, leads the quality testing of Novadip’s advanced cell-derived therapies, ensuring compliance with European and American drug development regulations.   🌟 Gaetane Metz, VP Quality Assurance, implements rigorous quality systems to guarantee the safety of our products for patients.   🌟 Justine Fourmeau, VP Clinical Manufacturing, oversees the production of clinical batches for our complex autologous and allogeneic bone products derived from adipose stem cells.   🌟 Hara Episkopou, VP Research & Development, is leading the development of a unique cell-free approach for skin regeneration and oncology treatments for solid tumors.   We’re incredibly grateful to every woman in our team at NOVADIP Biosciences S.A., helping us achieve our mission to advance bone healing and improve the quality of life for patients worldwide 🌍   #InternationalDayofWomenandGirlsinSTEM #WomeninSTEM #regenerativemedicine #orthopedics

Many thanks for this article to highlight the excellence of all the collaborators of Novadip to make life better for young and adult patients with major morbidities due to a bone non-healing. I'm very proud to conduct our therapeutic projects to the patients with a strong and inspired senior management team, a wonderful and faithful team to our values, challenging KOLs and investors who are supporting our efforts. "A song is like a dream, and you try to make it come true. They're like strange countries that you have to enter" Bob Dylan Science is like a song & opens new avenues

Nous recrutons (#hiring) pour le poste de Clinical Trial Assistant (Mont-Saint-Guibert, Walloon Region). Postulez dès maintenant ou partagez ce post avec votre réseau.

📢 Exciting Update: 12-Month Results from our Phase 1b/2a Trial of NVD003 for Treating Congenital Pseudarthrosis of the Tibia (CPT)    🦴 NVD003 is an innovative autologous therapy derived from adipose stem cells (ASC) with the potential to provide a groundbreaking single treatment for saving limbs and restoring mobility in children with CPT.   🌟 88% efficacy demonstrated across all patients (n=17) treated with NVD003 to date (nine adults with bone nonunion and eight children with Congenital Pseudarthrosis of the Tibia) 🌟 100% efficacy demonstrated when mechanical stability of fracture is achieved   “I am very pleased with the results I’ve seen in the children I have treated with NVD003,” said Prof. Pierre Louis Docquier, MD, PhD, a specialist in pediatric surgery at the University Hospital Saint-Luc in Brussels (Belgium) and EU principal investigator for this study. “For orthopedic surgeons, CPT fractures are among the most difficult to treat due to the underlying pathophysiology of the condition.”   🚀 With these promising results in hand, we are excited to announce the selection of clinical sites for our Phase 3 pivotal trial in CPT, with enrollment set to begin in Q2 2025. This brings us one step closer to offering pediatric surgeons a new treatment option for children with this rare and challenging condition.   Read the full press release below 👇 Denis Dufrane Judy Ashworth, MD    #Biotech #Orthopedics #Pediatrics #BoneHealing #RegenerativeMedicine #RareDisease #ClinicalTrials

🤔 Planning to attend #LSIUSA2025 in March? Don’t miss Denis Dufrane, CEO of Novadip, as he takes the stage on March 20 to share insights on our groundbreaking orthopedic solutions. He’ll be discussing how our innovations are transforming the healing of bone defects, spinal fusion, and more! Get all the details below 👇

🚀 We are proud to share that Denis Dufrane has been selected to present NOVADIP Biosciences S.A. at LSI USA ’25, March 17-21, 2025.    💥 Denis will present on March 20 at 10:30 AM - a unique opportunity for attendees to learn about Novadip's proprietary technology platform and discover how our regenerative tissue products are transforming the healing of large bone defects, non-union fractures, and spine fusion in a single treatment.   🤝 We look forward to engaging with fellow professionals and exploring potential collaborations.  💬 Send us a message to arrange a meeting with Denis at the event   #medtech #innovation #RegenerativeMedicine #Orthopedics #BoneHealing #LSI2025   https://lnkd.in/dQiNk4np

We are thrilled to announce the appointment of Drew Trivisonno to our Board of Directors 👏   With over three decades of expertise in debt and equity financing, plus 18 years as a leader in M&A, financing transactions, and building strategic partnerships, Drew is an exceptional addition to the Novadip team.    His experience will be pivotal as we accelerate our growth and move forward with our bold 2025 strategy, including a €50M Series C and a major expansion in the US #orthopedics market 🌍💡   “I am excited to join the Novadip board. The company’s clinical results have been outstanding, with NVD003 showing strong promise in pediatric patients and NVDX3 having excellent results in adults. This puts Novadip in a great position to become a world-leader in bone healing. I look forward to working with Denis and the entire Novadip team,” said Mr. Trivisonno.   Welcome to the team, Drew!    More info in this news release: https://lnkd.in/e2xKzcbP Denis Dufrane Eric Paul Pâques   #Appointment #Finance #RegenerativeMedicine #BoneHealing

 ✨ The Novadip team wishes you a happy and successful New Year! 🇺🇸 To kick off January, we are thrilled to announce that our CEO Denis Dufrane will be attending the J.P. Morgan Healthcare Conference in San Francisco next week to meet potential investors and partners, preparing for our Series C financing round targeting €50M. 💬 Drop us a message if you would like to arrange a meeting with Denis on Jan 13-16, to discuss our 3M3 tissue regeneration platform and the start of 3 pivotal trials in the US and in the EU for both our autologous and allogenic bone products. #RegenerativeMedicine #BoneHealing #Orthopedics #JPMorganHealth #JPM2025

  🗓️ With 2024 soon coming to an end, we are proud to reflect on a year of clinical excellence for NOVADIP Biosciences S.A. 🚀 2024 has been a year of clinical breakthroughs for Novadip: 👥 Following collaborative meetings with the FDA and European Medicines Agency, we are now ready to take our lead autologous therapy, NVD003, into a pivotal phase 3 for the treatment of congenital pseudoarthrosis of the tibia (CPT), a rare pediatric bone condition. 💪 NVD003 gained recognition from the European Commission for its potential to change lives. 🦴 We obtained positive interim results from our phase 1b/2a first-in-human trial for NVDX3 to heal distal radius fractures showing 90% of adult patients with these fractures reaching or steadily progressing towards complete bone healing at 6 months. ✅ Based on this promising safety and efficacy data, we received FDA approval for our Investigational New Drug Application (IND) for NVDX3 to move directly into a phase 2b trial in cervical spinal fusion, marking a big step forward in NVDX3’s development. 🌎 Our CEO Denis Dufrane and the team took our scientific work global, presenting at several international events including BIO International Convention in San Diego, LSI USA 24, Advanced Therapies in Belgium and The State of Spine Surgery 2024 meeting held in Mexico.  🥼 We strengthened our clinical advisory board welcoming Dr Alexander Ropper, Director of Spinal Neurosurgery at Bayer College of Medicine, to the team. In addition:  💶 We raised €9.6M for two collaborative projects focusing on ATMPs to accelerate the development of nanovesicle-based therapeutics for oncology and regenerative medicine purposes based on our 3M3 platform BioWin. As we look ahead to 2025, we are excited to continue pioneering innovative regenerative therapies to transform bone healing. Thank you to our dedicated team, advisors, partners, investigators, and patients for supporting our mission!   #biotech #clinicaltrial #regenerativemedicine #stemcells #celltherapy